Week 1
Scoping
We align with you on the problem, timeline, and deliverables.
What we do
We work with pre-seed to seed biotech, healthtech, and medtech companies to answer the commercial questions that generalist advice can't — because the right answer depends on regulatory pathway timing, pipeline stage, and deal-structure mechanics specific to your science.
What this typically looks like
Market landscaping grounded in regulatory and competitive timing, not just market size
Commercial and partnership strategy shaped by pipeline stage and deal-structure logic
Deal structure analysis — evaluating options against what the regulatory pathway actually permits
Focused research questions where a specific commercial decision hinges on domain-mechanism reasoning
Who we work with
Pre-seed to seed, post-institutional-funding companies led by scientist or technical founders with no in-house commercial function. If you have a decision where the regulatory or pipeline reality changes the right commercial answer, that's exactly where we help.
How an engagement works
Scoping
We align with you on the problem, timeline, and deliverables.
Mid-project check-in
We review progress and gather feedback to ensure we're on track.
Development
Our team conducts deep research, analysis, and synthesis.
Final presentation
You receive a written report and a presentation of findings and recommendations.
Cost
Scope and cost depend on the nature of the engagement, and are discussed directly before we begin. No fixed price list, no implied figure.

Senior Advisor

Our work is supported by Dr Paul Riley, Founder of Nexcea Life Sciences Consultancy, who serves as Senior Advisor to NBS.
Meet the TeamOur Latest Projects

Commercial viability and route-to-market strategy for a novel menstrual care product.
Market, commercial and funding strategy for computational protein-based biopesticides.
Commercial partnership strategy for a breath-based diagnostic platform in lung cancer.